

Wisconsin Cancer Reporting System

Quick Reference Guide

2021 Reporting Requirement Changes



Wisconsin Cancer Reporting System
Office of Health Informatics
Division of Public Health
Wisconsin Department of Health Services

The following describes the changes to required data items and coding instructions effective for cases diagnosed 1/1/2021 and after. There were no changes for 2019-2020. Refer to previous versions of the [Wisconsin Cancer Reporting System Coding and Data Requirement Manual](#) for a detailed summary of changes that went into effect in 2018 or earlier.

Only the requirements for submission to the Wisconsin Cancer Reporting System are described. Additional changes required for CoC Accredited Cancer Programs can be found in the [STORE](#).

Table of Contents

New Data Items Required for Cases Diagnosed 1/1/2021 and Later	1
NCDB COVID-related Data Items	1
COVID-19 Documentation	1
Name–Birth Surname	1
Medicare Beneficiary Identifier	1
Grade Post Therapy Clin (yc)	1
Gleason Data Items.....	1
Data Item Changes	2
Radiation Treatment Modality	2
Grade	2
Name Changes	2
HER2 Overall Summary and Schema Discriminator 2.....	2
ICD-O-3 Histology Revisions	3
Changes in Reportability	4
Now Reportable as of 1/1/2021 (not reportable prior to 2021)	4
No Longer Reportable (behavior change to 1) for cases diagnosed 1/1/2021 and after.....	4
Terms and Code Changes	5
Solid Tumor Rules	5
Appendix A: WCRS 2021 Required Data Items	6
Appendix B: FY2021 ICD-10-CM Casefinding List	10
Appendix C: WCRS Required SSDIs and Schema Discriminators	12
Site-Specific Data Items	12
Schema Discriminators	12
Appendix D: Manuals and Coding References	13
Standard Setters Reporting Requirements for 2021	13
2021 Required Coding and Abstracting Manuals	13
Coding References	14

This Wisconsin Cancer Reporting System Quick Reference Guide was created to serve as a summary of 2021 changes specific to Wisconsin reporting requirements for cases diagnosed beginning January 1, 2021.

Reporters should refer to appropriate manuals for complete coding instructions. See [Appendix D](#) for links to coding references and Manuals.

New Data Items Required for Cases Diagnosed 1/1/2021 and Later

NCDB COVID-related Data Items

COVID-related data items have been added to evaluate the impact of SARSCoV2 diagnosis on cancer patients. The first three data items denote patient status for the SARSCoV2 virus, and the fourth item denotes any treatment effects from hospital services disruptions related to the COVID19 pandemic.

- **NCDB_SARSCoV2_Test**
- **NCDB_SARSCoV2_Pos_Date**
- **NCDB_SARSCoV2_Pos**
- **NCDB_COVID19_Tx_Impact**

COVID-19 Documentation

- Collecting the four SARSCoV2 data items is required, when available.
- Documentation of COVID-19 and treatment delays in the text is required when available. **Make sure any text related to COVID-19 specifically includes the word “COVID-19”.** The standard use of the word “COVID-19” in the text will allow cases to be identified and isolated for further evaluation. Below is guidance on how to standardize this documentation in the text.

Text Field	Documentation Guidance
Lab Text	Date and results of COVID-19 and antibody testing (both positive and negative)
Treatment Text	If treatment is delayed, modified or not given due to COVID-19, add that detail to the corresponding treatment text field
Remarks Text	Record COVID-19 related ICD-10 codes specified in the medical record

Name–Birth Surname

Name–Birth Surname replaces Name—Maiden. This data item provides a gender-neutral data item name to record the last name (surname) of patients at birth, regardless of gender or marital status. Allowable values remain the same.

Medicare Beneficiary Identifier

Congress passed the Medicare Access and CHIP Reauthorization ACT to remove Social Security Number (SSN) from Medicare ID card and replace the existing Medicare Health Insurance Claim Numbers with a Medicare Beneficiary Identifier (MBI). The MBI is a step to minimize the risk of identity theft for Medicare beneficiaries and reduce opportunities for fraud.

Grade Post Therapy Clin (yc)

A new Grade Post Therapy Clin (yc) data item has been added. This data item records the grade of a solid primary tumor that has been microscopically sampled following neoadjuvant therapy or primary systemic/radiation therapy.

Gleason Data Items

The following SSDIs are now required for Prostate schemas. Prostate cancers are graded using Gleason score or pattern.

- **Gleason Patterns Clinical** represents primary and secondary patterns from needle core biopsy or TURP

- **Gleason Score Clinical** represents Gleason score based on adding the values for primary and secondary patterns in Needle Core Biopsy or TURP.
- **Gleason Patterns Pathological** represents primary and secondary patterns from prostatectomy or autopsy.
- **Gleason Score Pathological** represent Gleason score based on adding the values for primary and secondary patterns from prostatectomy or autopsy.
- **Gleason Tertiary Pattern** (required when available) represents the tertiary pattern value from prostatectomy or autopsy.

Data Item Changes

Radiation Treatment Modality

When the data item Phase I Radiation Treatment Modality was implemented in 2018 (V18) a code indicating *radiation was given but type of radiation unknown* was not included. Currently patients that receive radiation, but the modality is not known, are assigned a code 99. Code 99 is also used when it is unknown if radiation is given. This makes it difficult to distinguish patients that did receive radiation from those where it is unknown if radiation was given. Code 98 has been added to the data item Phase I Radiation Treatment Modality for cases where it is known radiation was given, but modality is unknown. Code 99 is only used when it is unknown if radiation was given. The new code and changed code may be used for all cases abstracted after the V21 implementation regardless of diagnosis year.

Grade

- Grade Post Therapy was renamed to Grade Post Therapy Path (yp) for clarity.
- The Grade fields for Lacrimal Gland have had Codes A-D removed, and Code 4 has been added. Since Code 1 and Code A both meant Well Differentiated (and similarly for codes 2 and B and codes 3 and C), it was decided to streamline the available codes. Code 4 was added to capture the Undifferentiated, anaplastic cases.
- The Grade fields for Lymphoma Ocular Adnexa have been modified.
 - Code 3 is now G3, more than 15 centroblasts per 10 HPF but with admixed centrocytes. Cases that used to have Code 4 should be changed to Code 3.
 - Code 4 is now G4, more than 15 centroblasts per 10 HPF but without centrocytes.
 - Code 5 has been removed. Cases that used to have Code 5 should be changed to Code 4.
 - Code L was removed. Low Grade (1 or 2) was determined to be a variation of Unknown, so cases that used to have L should be changed to Code 9.

Name Changes

- Grade Post Therapy → Grade Post Therapy Path (yp)
- Schema ID 00470 (Melanoma Skin) SSDI: LDH Pretreatment Level → LDH Level
- Schema ID 00470 (Melanoma Skin) SSDI: LDH Pretreatment Lab Value → LDH Lab Value

HER2 Overall Summary and Schema Discriminator 2

HER2 Overall Summary and **Schema Discriminator 2** will now be collected for additional schemas. See [Appendix C: WCRS Required SSDIs and Schema Discriminators](#) for details.

ICD-O-3 Histology Revisions

The Wisconsin Cancer Reporting System follows the reportability indicators in the official ICD-O references. Using the ICD-O references on the NAACCR and SEER websites jointly with the Wisconsin Cancer Reporting System Coding and Data Requirement Manual is required to accurately determine which conditions are reportable and the code for that condition. <https://www.naacr.org/icdo3/>

Beginning with cases diagnosed January 1, 2021, the ICD-O-3.2 is the preferred morphology coding reference manual. The following manuals must be used jointly to accurately determine case reportability (based on behavior code) and the final histology and behavior code for each case. It is recommended that these websites be bookmarked and used when abstracting each case.

- ICD-O-3.2 (second revision morphology):
http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
 - Also available on the NAACCR website: <https://www.naacr.org/icdo3/>
- 2021 ICD-O Histology and Behavior Code Update Tables: <https://www.naacr.org/icdo3/>
 - Changes are provided in 5 different tables based on the type of change. Plus 2 combination tables that list all changes in numerical (Table 6) and alphabetical (Table 7) order.
 - **This also results in a change to reportability for some conditions.**
- SEER Solid Tumor Coding Rules: <https://seer.cancer.gov/tools/solidtumor/>
- SEER Hematopoietic and Lymphoid Neoplasm Database: <https://seer.cancer.gov/tools/heme/>

How to use these references jointly to determine if the case is reportable:

1. Review the ICD-O-3.2 Excel document. Search for the term (or key letters from the term). Find the code that best matches the term. [2021 ICD O 3.2 Coding Table Excel](#)
2. For pre-2021 diagnoses, also check the 2021 ICD-O-3.2 Update Table (6 or 7) to confirm the code and behavior for pre-2021 diagnoses.
 - a. Table 6 (changes listed in numerical order): [2021 ICD O 3.2 Numeric Table](#)
 - b. Table 7 (changes listed in alphabetical order): [2021 ICD O 3.2 Coding Table](#)
3. If not in the ICD O 3.2, check SEER SINQ to see if the question has already been asked.
4. If not, submit a question to [Ask a SEER Registrar](#).

How to use these references jointly to determine the histology code and behavior:

1. Review the SEER Hematopoietic/Lymphoid Database or the SEER Solid Tumor Rules (MP/H) FIRST – whichever is appropriate based on site and histology.
2. If the SEER Heme Database or Solid Tumor Rules do not provide the coding instruction, review the ICD-O-3.2 Excel document. Search for the term (or key letters from the term). Find the code that best matches the term: [2021 ICD O 3.2 Coding Table Excel](#)
3. For pre-2021 diagnoses, also check the 2021 ICD-O-3.2 Update Table (6 or 7) to confirm the code and behavior for pre-2021 diagnoses.
 - a. Table 6 (changes listed in numerical order): [2021 ICD O 3.2 Numeric Table](#)
 - b. Table 7 (changes listed in alphabetical order): [2021 ICD O 3.2 Coding Table](#)
4. If not in the ICD O 3.2, check SEER SINQ to see if the question has already been asked.
5. If not, submit a question to [Ask a SEER Registrar](#).

Changes in Reportability

Beginning with cases diagnosed January 1, 2021, ICD-O-3.2 is the preferred morphology coding reference manual. The ICD-O-3.2 must be used jointly with the 2021 ICD-O Histology and Behavior Code Update tables, Hematopoietic and Lymphoid Neoplasm Database, and Solid Tumor (MP/H) rules to determine reportability as well as the final ICD-O code. A few of the major changes are listed below.

You must refer to the 2021 ICD-O Histology and Behavior Code Update tables for a complete list of changes:

<https://www.naaccr.org/icdo3/>

Now Reportable as of 1/1/2021 (not reportable prior to 2021)

- Early or evolving melanoma in situ (8720/2) and early or evolving melanoma (8720/3) is now reportable. Previously only reportable if stated to be a Clarks Level 1.
- Most GIST tumors (8936/3) are now behavior code 3. GIST with a Behavior Code of 1 is not reportable. GIST with a Behavior Code of 3 is reportable. The Date of Initial Diagnosis is the earliest date the GIST is found malignant, noted to have multiple foci, metastasis of positive lymph nodes.
- Nearly all neuroendocrine tumors are now behavior code 3.
- Nearly all thymomas (8580/3-8585/3) are now behavior code 3. Previously thymomas were only reportable if stated to be malignant. Now they are not reportable only if specifically stated to be benign.
 - The exceptions are: Microscopic thymoma or thymoma, benign (8580/0); Micronodular thymoma with lymphoid stroma (8580/1); Ectopic hamartomatous thymoma (8587/0)
- Lymphomatoid granulomatosis: Grades have been introduced. Grade 3 now has a behavior of 3 (9766/3) and is reportable. Grades 1 and 2 still have a behavior of 1 (9766/1) and are not reportable.
- 8380/2 Endometrioid intraepithelial neoplasia (C54.1) is now reportable.

No Longer Reportable (behavior change to 1) for cases diagnosed 1/1/2021 and after

Term(s)	ICD-O-3.2 2021 Code	Pre-2021 Code
Follicular carcinoma, encapsulated	8335/1	8335/3
Non-invasive EFVPTC; Non-invasive encapsulated follicular variant of papillary thyroid carcinoma EFVPTC (C73.9)	8343/1	8343/2 (2017-2020)
Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP); Non-invasive FTP (C73.9)	8349/1	8343/2 (2017-2020)
Immature teratoma of the lung (C34. _); thymus (C37.9); thyroid (C73.9)	9080/1	9080/3
Primary cutaneous CD4-positive small/medium T-cell lymphoma (C44. _)	9709/1	9709/3
Primary cutaneous CD30+ T cell lymphoproliferative disorder (C44. _)	9718/1	9718/3
Lymphoid papulosis (C44. _)	9718/1	9718/3
Hydroa vacciniforme-like lymphoproliferative disorder	9725/1	9725/3
Langerhans cell histiocytosis, (NOS, monostotic, polystotic)	9751/1	9751/3
Post-transplant lymphoproliferative disorder, NOS; PTLN, NOS	9971/1	9971/3

Terms and Code Changes

Dermatofibrosarcoma protuberans (C44)

- Behavior code for two terms changed from 3 to 1 and is no longer reportable.
 - Dermatofibrosarcoma protuberans NOS and Dermatofibrosarcoma NOS 8832/1
 - Pigmented dermatofibrosarcoma protuberans 8833/1
- Two new terms and codes have been introduced under 8832/3 and ARE reportable.
 - Dermatofibrosarcoma protuberans, fibrosarcomatous 8832/3
 - Dermatofibrosarcoma, sarcomatous 8832/3

Other code changes are provided in the table below:

Term(s)	ICD-O-3.2 2021 Code	Pre-2021 Code (CODE DELETED IN ICD-O-3.2)
Hemangiopericytoma, malignant	8815/3	9150/3
Burkitt cell leukemia (see also M-9687/3) (All terms – See Heme Database)	9687/3	9826/3
Precursor B-cell lymphoblastic lymphoma (see also M-9836/3)	9811/3	9728/3
Precursor B-cell lymphoblastic leukemia (see also M-9728/3)	9811/3	9836/3
Common ALL; c-ALL; Common precursor B ALL; Pre-B ALL; Pre-pre-B ALL; Pro-B ALL	9811/3	9836/3
Malignant lymphoma, small B lymphocytic, NOS (see also M-9823/3) (All terms – See Heme Database)	9823/3	9670/3
Precursor T-cell lymphoblastic lymphoma (see also M-9837/3)	9837/3	9729/3
Refractory neutropenia	9980/3	9991/3 (2010-2020)
Refractory thrombocytopenia	9980/3	9992/3 (2010-2020)

Solid Tumor Rules

- The Cutaneous Melanoma Solid Tumor Rules have been revised for 2021. Use the 2021 Solid Tumor Cutaneous Melanoma rules to determine the number of primaries to abstract and the histology to code for cases diagnosed 1/1/2021 forward.
- Download the rules for 2021 at: <https://seer.cancer.gov/tools/solidtumor/>
- The Other Sites rules are currently being revised. Continue to use the 2007 Other Sites MP/H rules for cases diagnosed in 2007-2021.
- Minor updates to other site-specific rules:
 - New histologies, codes, and terms from ICD-O-3.2 and the 2021 ICD-O Update added to tables
 - Corrections to histology tables
 - Additional H rules to enforce correct histology coding
 - Clarification of coding histology prior to neo-adjuvant therapy
 - Clarification to Malignant and Benign CNS Terms & Definitions: WHO Grade II and behavior

Appendix A: WCRS 2021 Required Data Items

This list is also available for download: [2021 Required Data Items](#) (Excel) | [2021 Required Data Items](#) (PDF)

Applicable for cases diagnosed on or after 1/1/2021 unless otherwise stated. New requirements shaded in gray. Links to NAACCR Data Dictionary included in Item # column.		
Item #	Item Name	Notes
570	Abstracted By	
550	Accession Number--Hosp	Required, when available
70	Addr at DX--City	
2330	Addr at DX--No & Street	
100	Addr at DX--Postal Code	
80	Addr at DX--State	
2335	Addr at DX--Supplementl	
230	Age at Diagnosis	
2158	AJCC Cancer Surveillance API Version Current	Generated by software
2159	AJCC Cancer Surveillance API Version Original	Generated by software
995	AJCC ID	Derived Field
523	Behavior Code ICD-O-3	
254	Birthplace--Country	Required, when available
252	Birthplace--State	Required, when available
3816	Brain Molecular Markers	Site-Specific Data Item
3817	Breslow Tumor Thickness	Site-Specific Data Item
501	Casefinding Source	
1910	Cause of Death	
610	Class of Case	
2152	CoC Accredited Flag	
90	County at DX Reported	
2090	Date Case Completed	
1260	Date Initial RX SEER	
1261	Date Initial RX SEER Flag	
580	Date of 1st Contact	
581	Date of 1st Contact Flag	
240	Date of Birth	
241	Date of Birth Flag	
390	Date of Diagnosis	
391	Date of Diagnosis Flag	
1750	Date of Last Contact	
1751	Date of Last Contact Flag	
490	Diagnostic Confirmation	
3827	Estrogen Receptor Summary	Site-Specific Data Item
3835	Fibrosis Score	Site-Specific Data Item
1790	Follow-Up Source	Required, when available
3838	Gleason Patterns Clinical	Site-Specific Data Item
3839	Gleason Patterns Pathological	Site-Specific Data Item
3840	Gleason Score Clinical	Site-Specific Data Item
3841	Gleason Score Pathological	Site-Specific Data Item
3842	Gleason Tertiary Pattern	Site-Specific Data Item. Required, when available.

Applicable for cases diagnosed on or after 1/1/2021 unless otherwise stated. New requirements shaded in gray. Links to NAACCR Data Dictionary included in Item # column.		
Item #	Item Name	Notes
3843	Grade Clinical	
3844	Grade Pathological	
1068	Grade Post Therapy Clin (yc)	Required, when available
3845	Grade Post Therapy Path (yp)	
3855	HER2 Overall Summary	Site-Specific Data Item
522	Histologic Type ICD-O-3	
1920	ICD Revision Number	
2116	ICD-O-3 Conversion Flag	
2410	Institution Referred From	
2420	Institution Referred To	
410	Laterality	
3932	LDH Lab Value	Site-Specific Data Item
1182	Lymphovascular Invasion	Required, when available
150	Marital Status at DX	
2300	Medical Record Number	
2315	Medicare Beneficiary Identifier	Required, when available.
1112	Mets at DX-Bone	
1113	Mets at DX-Brain	
1114	Mets at Dx-Distant LN	
1115	Mets at DX-Liver	
1116	Mets at DX-Lung	
1117	Mets at DX-Other	
3890	Microsatellite Instability (MSI)	Site-Specific Data Item
470	Morph Coding Sys--Current	Generated by software
50	NAACCR Record Version	Generated by software
2280	Name--Alias	
2232	Name--Birth Surname	This data item was introduced to be a gender-neutral birth-surname data item, analogous to Name--Maiden
2240	Name--First	
2230	Name--Last	
2250	Name--Middle	
2270	Name--Suffix	
3946	NCDB--COVID19--Tx Impact	Required, when available. Applies to Diagnosis Year 2020 forward.
3944	NCDB--SARSCoV2--Pos	Required, when available. Applies to Diagnosis Year 2020 forward.
3945	NCDB--SARSCoV2--Pos Date	Required, when available. Applies to Diagnosis Year 2020 forward.
3943	NCDB--SARSCoV2--Test	Required, when available. Applies to Diagnosis Year 2020 forward.
2475	NPI--Physician--Follow-Up	Required, when available
2465	NPI--Physician--Managing	Required, when available
545	NPI--Reporting Facility	
1990	Over-ride Age/Site/Morph	
2040	Over-ride Histology	
2070	Over-ride Leuk, Lymphoma	

Applicable for cases diagnosed on or after 1/1/2021 unless otherwise stated. New requirements shaded in gray.
 Links to NAACCR Data Dictionary included in Item # column.

Item #	Item Name	Notes
2078	Over-ride Name/Sex	
2071	Over-ride Site/Behavior	
2073	Over-ride Site/Lat/EOD	
2074	Over-ride Site/Lat/Morph	
2030	Over-ride Site/Type	
2020	Over-ride Surg/DxConf	
1506	Phase I Radiation Treatment Modality	
2470	Physician--Follow-Up	
2460	Physician--Managing	
1944	Place of Death--Country	
1942	Place of Death--State	
630	Primary Payer at DX	
400	Primary Site	
3915	Progesterone Receptor Summary	Site-Specific Data Item
3920	PSA (Prostatic Specific Antigen) Lab Value	Site-Specific Data Item
160	Race 1	
161	Race 2	
162	Race 3	
163	Race 4	
164	Race 5	
1430	Reason for No Radiation	
1340	Reason for No Surgery	
10	Record Type	Generated by software
830	Regional Nodes Examined	
820	Regional Nodes Positive	
540	Reporting Facility	
1460	RX Coding System--Current	Generated by software
1240	RX Date BRM	
1241	RX Date BRM Flag	
1220	RX Date Chemo	
1221	RX Date Chemo Flag	
1230	RX Date Hormone	
1231	RX Date Hormone Flag	
3170	RX Date Mst Defn Srg	
3171	RX Date Mst Defn Srg Flag	
1250	RX Date Other	
1251	RX Date Other Flag	
1210	RX Date Radiation	
1211	RX Date Radiation Flag	
1200	RX Date Surgery	
1201	RX Date Surgery Flag	
3230	RX Date Systemic	
3231	RX Date Systemic Flag	
1410	RX Summ--BRM	
1390	RX Summ--Chemo	

Applicable for cases diagnosed on or after 1/1/2021 unless otherwise stated. New requirements shaded in gray.
 Links to NAACCR Data Dictionary included in Item # column.

Item #	Item Name	Notes
1400	RX Summ--Hormone	
1420	RX Summ--Other	
1292	RX Summ--Scope Reg LN Sur	
1294	RX Summ--Surg Oth Reg/Dis	
1290	RX Summ--Surg Prim Site	
1380	RX Summ--Surg/Rad Seq	
1639	RX Summ--Systemic/Sur Seq	
3250	RX Summ--Transplnt/Endocr	
1285	RX Summ--Treatment Status	
2660	RX Text--BRM	
2640	RX Text--Chemo	
2650	RX Text--Hormone	
2670	RX Text--Other	
2620	RX Text--Radiation (Beam)	
2630	RX Text--Radiation Other	
2610	RX Text--Surgery	
3926	Schema Discriminator 1	Site-Specific Data Item
3927	Schema Discriminator 2	Site-Specific Data Item
3800	Schema ID	Derived Field
2117	Schema ID Version Current	Generated by software
2118	Schema ID Version Original	Generated by software
560	Sequence Number--Hospital	
220	Sex	
450	Site Coding Sys--Current	Generated by software
2320	Social Security Number	
190	Spanish/Hispanic Origin	
764	Summary Stage 2018	
2360	Telephone	
2550	Text--DX Proc--Lab Tests	
2560	Text--DX Proc--Op	
2570	Text--DX Proc--Path	
2520	Text--DX Proc--PE	
2540	Text--DX Proc--Scopes	
2530	Text--DX Proc--X-ray/Scan	
2590	Text--Histology Title	
2690	Text--Place of Diagnosis	
2580	Text--Primary Site Title	
2680	Text--Remarks	
2600	Text--Staging	
320	Text--Usual Industry	
310	Text--Usual Occupation	
756	Tumor Size Summary	
500	Type of Reporting Source	
2170	Vendor Name	Generated by software
1760	Vital Status	

Appendix B: FY2021 ICD-10-CM Casefinding List

The Comprehensive ICD-10-CM Casefinding Code List for Reportable Tumors is included below for your reference. The full ICD-10-CM Casefinding List, which includes both Comprehensive and Supplemental Lists*, is also available for download in PDF and Excel formats:

- [ICD-10-CM Casefinding List, 2021 \(PDF Format\)](#)
- [ICD-10-CM Casefinding List, 2021 \(Excel Format\)](#)

*Use of Supplemental Lists is not required by the Wisconsin Cancer Reporting System. The supplementary list contains neoplasm-related secondary conditions for which there should also be a primary diagnosis of a reportable neoplasm. Facilities can use the supplementary list to identify visits that were either missed or miscoded or that may provide follow-up information.

Comprehensive ICD-10-CM Casefinding Code List for Reportable Tumors	
<i>Effective dates: 10/01/2020 – 09/30/2021</i>	
ICD-10-CM	Diagnosis [with preferred ICD-O-3 terminology]
C00.- - C43.-, C4A.-, C45.- - C48.-, C49.- C96.-	Malignant neoplasms (excluding category C44 and C49.A), stated or presumed to be primary (of specified site) and certain specified histologies
C44.00, C44.09	Unspecified/other malignant neoplasm of skin of lip
C44.10-, C44.19-	Unspecified/other malignant neoplasm of skin of eyelid
C44.13-	Sebaceous cell carcinoma of skin of eyelid, including canthus Note: Effective 10/1/2018
C44.20-, C44.29-	Unspecified/other malignant neoplasm skin of ear and external auricular canal
C44.30-, C44.39-	Unspecified/other malignant neoplasm of skin of other/unspecified parts of face
C44.40, C44.49	Unspecified/other malignant neoplasm of skin of scalp & neck
C44.50-, C44.59-	Unspecified/other malignant neoplasm of skin of trunk
C44.60-, C44.69-	Unspecified/other malignant neoplasm of skin of upper limb, incl. shoulder
C44.70-, C44.79-	Unspecified/other malignant neoplasm of skin of lower limb, including hip
C44.80, C44.89	Unspecified/other malignant neoplasm of skin of overlapping sites of skin
C44.90, C44.99	Unspecified/other malignant neoplasm of skin of unspecified sites of skin
C49.A-	Gastrointestinal Stromal Tumors Note: All GIST tumors are now reportable starting in 2021 (per ICD-O-3.2), including GIST, NOS
D00.- - D09.-	In-situ neoplasms <ul style="list-style-type: none"> • Note: Carcinoma in situ of the cervix (CIN III-8077/2) and Prostatic Intraepithelial Carcinoma (PIN III-8148/2) are not reportable
D18.02	Hemangioma of intracranial structures and any site
D32.-	Benign neoplasm of meninges (cerebral, spinal and unspecified)
D33.-	Benign neoplasm brain and other parts of central nervous system
D35.2 – D35.4	Benign neoplasm of pituitary gland, craniopharyngeal duct and pineal gland
D42.- – D43.-	Neoplasm of uncertain behavior of the brain & spinal cord, meninges, endocrine glands & other & unspecified parts of nervous system
D44.3 – D44.5	Neoplasm of uncertain behavior of the pituitary gland, craniopharyngeal duct and pineal gland
D45	Polycythemia vera [ICD-O3 9950/3] <ul style="list-style-type: none"> • ICD-10-CM Coding instruction note: Excludes familial polycythemia (ICD-10-CM C75.0), secondary polycythemia (ICD-10-CM D75.1)

Comprehensive ICD-10-CM Casefinding Code List for Reportable Tumors

Effective dates: 10/01/2020 – 09/30/2021

ICD-10-CM	Diagnosis [with preferred ICD-O-3 terminology]
D46.-	Myelodysplastic syndromes (9980, 9982, 9983, 9985, 9986, 9989, 9991, 9992)
D47.02	Systemic mastocytosis
D47.1	Chronic myeloproliferative disease(9963/3,9975/3) <ul style="list-style-type: none"> • ICD-10-CM Coding instruction note: Excludes the following: <ul style="list-style-type: none"> ○ Atypical chronic myeloid leukemia BCR/ABL-negative (C92.2_) ○ Chronic myeloid leukemia BCR/ABL-positive (C92.1_) ○ Myelofibrosis & Secondary myelofibrosis (D75.81) ○ Myelophthisic anemia & Myelophthisis (D61.82)
D47.3	Essential thrombocythemia [ICD-O3 9962/3] <ul style="list-style-type: none"> • Includes: Essential thrombocytosis, idiopathic hemorrhagic thrombocythemia
D47.4	<ul style="list-style-type: none"> • Osteomyelofibrosis (9961/3) • Includes: Chronic idiopathic myelofibrosis Myelofibrosis (idiopathic) (with myeloid metaplasia) Myelosclerosis (megakaryocytic) with myeloid metaplasia) Secondary myelofibrosis in myeloproliferative disease
D47.9	Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified [ICD-O3 9970/1 or 9931/3]
D47.Z-	Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified [ICD-O3 9960/3, 9970/1, 9971/3, or 9931/3]
D49.6, D49.7	Neoplasms of unspecified behavior of brain, endocrine glands and other CNS
D72.110	Idiopathic hypereosinophilic syndrome [HES]
D72.111	Lymphocytic Variant Hypereosinophilic Syndrome [LHES]
D72.118	Other hypereosinophilic syndrome
D72.119	Hypereosinophilic syndrome [HES], unspecified
R85.614	Cytologic evidence of malignancy on smear of anus
R87.614	Cytologic evidence of malignancy on smear of cervix
R87.624	Cytologic evidence of malignancy on smear of vagina

Appendix C: WCRS Required SSDIs and Schema Discriminators

For cases diagnosed on January 1, 2018 and later, the SSDIs and Schema Discriminators in the tables below are required to be reported to the WCRS. While the majority of these have been required since 2018, there have been new items and updates to existing items added for 2021. Refer to the [SSDI manual](#) for most current version of the site-specific codes and coding structures.

Site-Specific Data Items

Site	SSDI
Brain	Brain Molecular Markers
Breast	Estrogen Receptor Summary
	Progesterone Receptor Summary
	HER2 Overall Summary
Colon and Rectum	Microsatellite Instability (MSI)
Esophagus and Stomach*	HER2 Overall Summary
Liver	Fibrosis Score
Melanoma	Breslow Tumor Thickness
Prostate	PSA Lab Value
Prostate	Gleason Patterns Clinical
	Gleason Score Clinical
	Gleason Patterns Pathological
	Gleason Score Pathological
	Gleason Tertiary Pattern (<i>when available</i>)
*HER2 Overall Summary has existed in other schemas but are new to Esophagus and Stomach for 2021 cases.	

Schema Discriminators

Schema Discriminator	Required For These Sites
Schema Discriminator 1	<ul style="list-style-type: none"> Bile Ducts Distal/Bile Ducts Perihilar/Cystic Duct Esophagus GE Junction (EGJ)/Stomach Lymphoma and Leukemia (9591/3) Lacrimal Gland/Sac Melanoma Ciliary Body/Melanoma Iris Nasopharynx/Pharyngeal Tonsil Occult Head and Neck Lymph Nodes Plasma Cell Myeloma Terminology Primary Peritoneum Tumor Thyroid Gland/Thyroglossal Duct Urethra/Prostatic Urethra
Schema Discriminator 2*	<ul style="list-style-type: none"> Esophagus and Esophagogastric Junction (8020) Oropharyngeal p16 Soft Tissue Sarcoma (C473, C475, C493-C495)

*Schema Discriminator 2 is now required for C473, C475, C493-C495 with respect to Soft Tissue Abdomen and Thoracic or Soft Tissue Trunk and Extremities. These sites can be an external structure or internal viscera, and correct classification within a schema depends on this distinction. For those cases diagnosed in 2018-2020 and already collected, the value '8' should be automatically assigned to indicate the distinction was not captured and these cases will remain in Soft Tissue Abdomen and Thoracic.

Appendix D: Manuals and Coding References

The following references are required to code certain data items. Coding instructions for items from these sources are not reproduced in this document to avoid redundancy and possible conflict when the primary manuals are updated. For each, use the most current version applicable for the diagnosis year.

Standard Setters Reporting Requirements for 2021

Although there are fewer changes for 2021 than there were for 2018, each standard setting agency has specific reporting requirements that can be found in the [NAACCR 2021 Implementation Guidelines](#).

Additional Standard Setter reporting requirements available:

- CoC Reporting Requirements
- STORE Manual Data Item Reduction
- CDC NPCR Reporting Requirements
- Staging Requirements for 2021 Diagnosis

2021 Required Coding and Abstracting Manuals

For cases diagnosed on or after January 1, 2021, WCRS requires reporters to use the following manuals and resources:

- **WCRS Coding and Data Requirement Manual:**
<https://www.dhs.wisconsin.gov/wcrs/reporterinfo/manual.htm>
- **WCRS Reporting Facility List (Excel Format):**
<https://www.dhs.wisconsin.gov/wcrs/reporterinfo/v21-facilitylist-wi-facilities.xlsx>
- **WCRS Wisconsin-licensed Physicians List (Excel Format):**
<https://www.dhs.wisconsin.gov/wcrs/reporterinfo/v21-physicianlist-wi-facilities.xlsx>
- **ICD-O-3.2 (Second Revision Morphology):**
http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
- **AJCC Cancer Staging Manual, Eighth Edition (plus Chapter revisions):**
<http://sxc.cancerstaging.org/references-tools/deskreferences/Pages/default.aspx>
- **Site-Specific Data Items (SSDIs):**
<https://apps.naacr.org/ssdi/list/>
- **Grade Manual:**
<https://www.naacr.org/SSDI/Grade-Manual.pdf>
- **SEER Solid Tumor Coding Rules (MP/H):**
<https://seer.cancer.gov/tools/solidtumor/>
- **SEER Hematopoietic and Lymphoid Neoplasm Manual and Database:**
<https://seer.cancer.gov/tools/heme/>
- **SEER Summary Stage 2018:**
<https://seer.cancer.gov/tools/ssm/>
- **SEER*Rx – Interactive Drug Database:**
<http://seer.cancer.gov/tools/seerrx>
- **SEER ICD-10-CM Casefinding Lists:**
<https://seer.cancer.gov/tools/casefinding/>
- **CTR Guide to Coding Radiation Therapy Treatment:**
<https://www.facs.org/quality-programs/cancer/ncdb/call-for-data/cocmanuals>

Coding References

- **AJCC Cancer Staging Manual, Eighth Edition (plus Chapter revisions):**
<http://sxc.cancerstaging.org/references-tools/deskreferences/Pages/default.aspx>

The AJCC Cancer Staging Manual is used by physicians and health care professionals throughout the world to facilitate the uniform description and reporting of neoplastic diseases. Proper classification and staging of cancer are essential for the physician to assign proper treatment, evaluate results of management and clinical trials, and to serve as the standard for local, regional and international reporting on cancer incidence and outcome.

- **ACoS Standards for Oncology Registry Entry (STORE):**
<https://www.facs.org/quality-programs/cancer/ncdb/call-for-data>

Developed by the Commission on Cancer (CoC) of the American College of Surgeons (ACS) for its CoC accredited programs. It defines the data items and coding instructions required for CoC accredited programs.

- **SEER Hematopoietic and Lymphoid Neoplasm Manual and Database:**
<https://seer.cancer.gov/tools/heme/>

- **Grade Manual:**
<https://www.naaccr.org/SSDI/Grade-Manual.pdf>

The Grade Coding Instructions and Tables (Grade Manual) is the primary resource for documentation and coding instructions for Grade for cases diagnosed on or after January 1, 2018.

- **ICD-O-3.2 (second revision morphology):**
http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577

- **SEER*Rx – Interactive Drug Database:**
<https://seer.cancer.gov/registrars/>

Site Specific Data Items (SSDIs):
<https://apps.naaccr.org/ssdi/list/>

- **SEER Solid Tumor Coding Rules (MP/H):**
<https://seer.cancer.gov/tools/solidtumor/>

The Solid Tumor Coding Rules contain site-specific rules for lung, breast, colon, melanoma of the skin, head and neck, kidney, renal pelvis/ureter/bladder and malignant and non-malignant brain primaries. A separate set of rules addresses the specific and general rules for all other solid tumor sites. The multiple primary rules guide and standardize the process of determining the number of primary tumors or abstracts to be created. The histology rules contain detailed histology coding instructions.

- **SEER Summary Stage 2018:**
<https://seer.cancer.gov/tools/ssm/>

Summary Stage is the most basic way of categorizing how far a cancer has spread from its point of origin. Historically, Summary Stage has also been called General Stage, California Stage, historic stage, and SEER Stage. The 2018 version of Summary Stage applies to every site and/or histology combination, including lymphomas and leukemias. Summary Stage is a combination of the most precise clinical and pathological documentation of the extent of disease.